Clinical trial register · European Union · CTIS

Clinical Trials in France, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2557 most recently authorised of 12788 total CTIS records — a stated recency window, not the full historical archive. Synced 08 Nov 2026, 03:17 UTC

2557

Shown in this register

most recently authorised

12,788

Total on CTIS

full historical archive

789

Phase III

within the shown window

Top member states

Spain 1074 France 933 Germany 893 Italy 777 Poland 614 Netherlands 544

Narrow the registerReset

Search within results

Phase

Lead sponsor

Member state

All 28 states

Trials with a site in France

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase II

"EURbG2": A European prospective study of patients with unilateral retinoblastoma requiring enucleation, either first-line or after neoadjuvant chemotherapy, with analysis of histological risk factors and biomarkers at baseline and during follow-up

2024-515962-15-00Retinoblastoma

DrugsThiotepa·Vincristine·Etoposide·Cyclophosphamide

Institut Curie

Eye Diseases

France

06/11/2026

Phase II

A Phase IIb multicenter, randomized, double-blind, placebo-controlled, dose-range study to assess the efficacy and safety of GIA632 in participants with moderate to severe cutaneous lichen planus, followed by an extension period

2025-522300-25-00Cutaneous lichen planus

DrugGIA632

Novartis Pharma AG

Immune System Diseases

Italy, Germany, Spain, France

02/11/2026

Phase II

Multicenter, open-label, randomized Phase 2 study evaluating continuous weekly dosing of ficerafusp alfa (BCA101) in combination with pembrolizumab versus an alternative dosing regimen for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma

2026-526741-10-00Recurrent or Metastatic Head and Neck Squamous Cell Carcino…

DrugsFicerafusp alfa·Pembrolizumab

Bicara Therapeutics Inc.

Neoplasms

Netherlands, Spain, France, Italy, Belgium, Poland, Germany

30/10/2026

Phase II

A pilot TriAl of psilocybiN-Assisted psychotherapy for the treatment Of Sex addiction

2026-527083-32-00Sex addiction

DrugPsilocybine

Centre Hospitalier Universitaire De Nantes

Behavior and Behavior Mechanisms

France

30/10/2026

Phase II

(VVD-133214-02 / 23236) A Phase 2, Randomized, Open-label Study of VVD-133214 in Combination with Pembrolizumab compared to Pembrolizumab Monotherapy in Participants with Advanced Colorectal Adenocarcinoma (CRC) Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (DMMR)

2026-525507-26-00Advanced colorectal adenocarcinoma

DrugsVVD-133214·Pembrolizumab

Vividion Therapeutics Inc.

Neoplasms

Greece, Portugal, Italy, France, Belgium, Germany, Spain

30/10/2026

Phase II

Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial

2025-523118-97-00HIV-1 Infection

DrugsBaricitinib·Sirolimus

ANRS Maladies Infectieuses Emergentes

Virus Diseases

France

27/10/2026

Phase II

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)

2026-526472-23-00Non-Small Cell Lung Cancer

Verastem Inc.

Neoplasms

France, Spain, Germany, Italy, Belgium

27/10/2026

Phase II

A Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Trial to Assess the Efficacy, Safety, and Tolerability of AGMB-447 in Participants with Idiopathic Pulmonary Fibrosis

2026-526404-71-00Idiopathic Pulmonary Fibrosis

DrugSalbutamol

Agomab Spain S.L.U.

Respiratory Tract Diseases

Poland, France, Belgium, Italy, Spain, Portugal, Netherlands, Germany

27/10/2026

Phase II

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF RO7568282 IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE

2026-526158-14-00Early Symptomatic Alzheimer’s Disease (AD)

DrugRO7568282

F. Hoffmann-La Roche AG

Nervous System Diseases

Spain, Belgium, Denmark, France, Poland, Italy, Germany, Ireland

27/10/2026

Phase II

A Phase 2 open-label trial to investigate the long term safety of VO659 administered intrathecally in participants with Huntington’s disease and spinocerebellar ataxia type 1 and 3

2026-526408-60-00Spinocerebellar ataxia types 1, 3 and Huntington's disease

Vico Therapeutics B.V.

Nervous System Diseases

Denmark, France, Netherlands, Germany

26/10/2026

Phase II

Aspire-202: A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137 in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B in the North America and Europe Regions

2025-524159-30-00Chronic Hepatitis B

DrugAHB-137

Ausperbio Therapeutics Inc.

Virus Diseases

France, Italy, Spain

22/10/2026

Phase II

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants with Early-Stage Parkinson’s Disease

2025-524064-37-00Parkinson’s Disease (PD)

DrugRO7568282

F. Hoffmann-La Roche AG

Nervous System Diseases

Germany, Italy, Netherlands, Poland, France, Ireland, Spain, Austria

21/10/2026

Phase II

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)

2026-526473-42-00Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma

DrugsPanitumumab·Erbitux·Fluorouracil·Oxaliplatin

Verastem Inc.

Neoplasms

Italy, Spain, France, Germany, Belgium

20/10/2026

Phase II

EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC.

2025-522985-60-00Non-small cell lung cancer

DrugsIvonescimab·Paclitaxel·Carboplatin

European Organisation For Research And Treatment Of Cancer

Neoplasms

Slovenia, Spain, Germany, France, Austria, Netherlands, Italy, Greece

19/10/2026

Phase II

A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Mezagitamab (TAK-079) in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

2026-526239-20-00Late antibody mediated rejection (AMR)

DrugMezagitamab

Takeda Development Center Americas Inc.

Immune System Diseases

Germany, France

19/10/2026

Phase II

A pilot multicentric open study assessing the efficacy and safety of NEMOlizumab in patients ≥12yo with Dystrophic Epidermolysis bullosa; NEMODE

2026-526417-28-00dystrophic epidermolysis bullosa

DrugNemolizumab

Centre Hospitalier Universitaire De Nice

Skin and Connective Tissue Diseases

France

16/10/2026

Phase II

EVITA - Epcoritamab plus Venetoclax plus Ibrutinib in patients with chronic lymphocytic leukemia with TP53 Alterations

2025-520893-20-00Chronic lymphocytic leukemia, B-cell small lymphocytic lymp…

DrugsEpcoritamab·Ibrutinib·Venetoclax

LYSARC

Hemic and Lymphatic Diseases

Belgium, France

16/10/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

2025-525115-16-00Pulmonary Hypertension Associated with Interstitial Lung Di…

DrugNS-863

Ns Pharma Inc.

Respiratory Tract Diseases

Italy, Greece, Portugal, France, Belgium, Germany, Spain

16/10/2026

Phase II

A randomized, double-blind, placebo-controlled, multicenter Phase 2a/b study assessing the efficacy, safety and tolerability of DDY391 in participants with Sjögren's Disease

2025-524513-92-00Sjögren's Disease

Novartis Pharma AG

Immune System Diseases

Portugal, Bulgaria, Belgium, Spain, Denmark, France, Slovakia, Poland, Hungary, Italy, Netherlands, Germany, Austria

15/10/2026

Phase II

A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment with Efimosfermin Alfa in Adult Participants with Alcohol-related Liver Disease (ALD)

2026-526391-23-00Liver Diseases, Alcoholic

Glaxosmithkline Research & Development Limited

Digestive System Diseases

Spain, Denmark, Italy, Poland, France, Germany, Greece

12/10/2026

Phase II

An open label, multi-center alpelisib roll-over study to assess long-term safety in participants who have completed a Novartis sponsored alpelisib (BYL719) study and are judged by the Investigator to benefit from continued treatment with alpelisib.

2026-525890-38-00• PROS (PIK3CA‑Related Overgrowth Spectrum) and, • Breast N…

DrugsAlpelisib·Fulvestrant

Novartis Pharma AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

France, Italy, Bulgaria, Slovakia, Finland, Spain

12/10/2026

Phase II

MOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.

2025-522058-38-00HER2-positive rare cancer, HER2 positive non-small cell lun…

DrugTrastuzumab deruxtecan

Centre Leon Berard

Pathological Conditions, Signs and Symptoms

France

09/10/2026

Phase II

CombiMucor - Efficacy of combination therapy with isavuconazole and intermittent high doses liposomal amphotericin B for the treatment of mucormycosis

2025-521505-40-00Adults with mucormycosis

DrugAmphotericin B

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

09/10/2026

Phase II

2025-525114-38-00Pulmonary Arterial Hypertension (PAH)

DrugNS-863

Ns Pharma Inc.

Respiratory Tract Diseases

France, Germany, Poland, Italy, Belgium, Spain, Greece

08/10/2026

Phase II

LIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors

2025-524515-37-00Neoplasm malignant

DrugBelzutifan

Merck Sharp & Dohme LLC

Neoplasms

Belgium, Spain, Denmark, Italy, France

05/10/2026

Phase II

Hex-SUB1-IPC 2025-067 - PROOF OF CONCEPT: FEASIBILITY OF PHOTODYNAMIC DIAGNOSIS IN BLADDER CANCER PATIENTS WITH SUB-ONE-HOUR INSTILLATION TIME OF HEXAMINOLEVULINATE (HEXVIX®)

2026-526917-27-00primary or recurrent confirmed papillary bladder cancer (BC)

DrugHexvix

Institut Paoli Calmettes

Neoplasms

France

30/09/2026

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults with Phenylketonuria (PKU)

2026-525622-37-01Phenylketonuria

Maze Therapeutics Inc.

Nutritional and Metabolic Diseases

Germany, France, Netherlands

29/09/2026

Phase II

FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations

2026-525763-40-00Patients with previously untreated chronic lymphocytic leuk…

DrugsNemtabrutinib·Obinutuzumab·Venetoclax

French Innovative Leukemia Organization (F.I.L.O.).

Hemic and Lymphatic Diseases

France

25/09/2026

Phase II

A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease

2026-525197-19-00Fibrostenosing Crohn’s Disease

DrugOntunisertib

Agomab Spain S.L.U.

Digestive System Diseases

France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands

21/09/2026

Phase II

J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

2026-525480-41-00Pulmonary Disease, Chronic Obstructive

DrugBrenipatide

Eli Lilly & Co.

Respiratory Tract Diseases

Denmark, France, Romania, Czechia, Poland, Hungary, Germany, Austria

15/09/2026

Phase II

Interventional, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial of Lu AF28996 in adults with Parkinson’s disease experiencing motor fluctuations.

2025-524655-30-00Parkinson’s disease

H. Lundbeck A/S

Nervous System Diseases

Czechia, France, Spain, Poland, Italy, Germany, Sweden

15/09/2026

Phase II

A multicenter, randomized, double-blind, placebo- controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)

2025-524496-23-00Papulopustular Rosacea (PPR)

Novartis Pharma AG

Skin and Connective Tissue Diseases

Bulgaria, Spain, France, Italy, Germany

14/09/2026

Phase II

COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases

2025-524215-36-00Patients with non resectable pMMR/MSS BRAF wt mCRC, without…

DrugsFolinic acid·Ivonescimab·Fluorouracil·Leucovorin

Unicancer

Neoplasms

France

11/09/2026

Phase II

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy

2026-526218-10-00Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (S…

Argenx

Immune System Diseases

Germany, Estonia, Lithuania, Portugal, Slovakia, Hungary, Romania, Poland, Spain, Austria, Belgium, France, Bulgaria

08/09/2026

Phase II

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

2026-525170-19-00Locally Advanced or Metastatic Non-Small Cell Lung Cancer (…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Italy, Spain, Romania, Germany, France

07/09/2026

Phase II

"Evaluation of the impact of the dose of heparin on the occurrence of DWI ischemic lesions after embolization of unruptured intracranial aneurysm" "HARMONI"

2026-526530-13-00Intracranial aneurysms

DrugsAcetylsalicylic acid·Ticagrelor

Centre Hospitalier Universitaire De Bordeaux

Nervous System Diseases

France

07/09/2026

Phase II

Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)

2026-525479-15-00Venous Thromboembolism

DrugRBD4059

Ribocure Pharmaceuticals AB

Cardiovascular Diseases

Poland, Romania, France, Bulgaria

04/09/2026

Phase II

BiFAST : A phase II trial evaluating fixed dose and faster ramp-up of epcoritamab with lenalidomide for 3L relapse/refractory large B-cell lymphoma after CAR T-cells therapy in 2nd line

2025-520895-24-003L relapse/refractory large B-cell lymphoma after CAR T-cel…

DrugsEpcoritamab·Lenalidomide

LYSARC

Hemic and Lymphatic Diseases

France

02/09/2026

Phase II

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

2025-524748-37-00Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

DrugCenegermin

Dompe' Farmaceutici S.p.A.

Eye Diseases

Denmark, Italy, Germany, Hungary, Netherlands, Spain, Belgium, France, Portugal

01/09/2026

Phase II

A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1

2026-525848-15-00GBA1-associated Parkinson’s disease

Vanqua Bio Inc.

Nervous System Diseases

Netherlands, France, Spain, Germany

01/09/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis

2025-521901-42-00Idiopathic Pulmonary Fibrosis (IPF)

Contineum Therapeutics Inc.

Respiratory Tract Diseases

Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain

26/08/2026

Phase II

C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer

2025-524825-42-00Early-Stage Resectable or Locally Advanced Unresectable Non…

Pfizer Inc.

Neoplasms

Spain, France, Italy, Ireland, Germany, Poland

26/08/2026

Phase II

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

2025-524130-26-00Gastrointestinal Cancers

Genmab A/S

Neoplasms

Italy, Belgium, France, Spain, Denmark, Netherlands, Germany

26/08/2026

Phase II

DIRECTION- Discontinuation versus continuation of riociguat monotherapy in chronic thromboembolic pulmonary hypertension successfully treated with balloon pulmonary angioplasty

2026-525351-81-00chronic thromboembolic pulmonary hypertension

DrugRiociguat

Assistance Publique Hopitaux De Paris

Cardiovascular Diseases

France

25/08/2026

Phase II

[68]GA-FAPI-46 PET/CT for the diagnosis of metastatic lesions in patients with lobular breast cancer (ICL). FAPICL

2025-524897-40-00invasive lobular carcinomas of the breast

Drug[68Ga]Ga-FAPI-46

Hospices Civils De Lyon

Diagnosis

France

25/08/2026

Phase II

Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)

2025-524905-34-00Solid tumor

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Greece, Hungary, Poland, Belgium, Spain, Netherlands, Germany, France, Portugal, Italy, Romania

25/08/2026

Phase II

Treatment of post-traumatic stress disorder with medical nitrous oxide combined with exposure to a personal traumatic script: a multicenter randomized controlled trial (POTESTA)

2026-525826-39-00Post-Traumatic Stress Disorder

Centre Hospitalier Regional Universitaire De Tours

Mental Disorders

France

19/08/2026

Phase II

A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination with Lenvatinib versus Lenvatinib in Participants with Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab

2025-524591-30-00Hepatocellular Carcinoma

Akeso Biopharma Co. Ltd.

Neoplasms

Poland, France, Spain, Italy

18/08/2026

Phase II

FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

2025-523632-39-00acute myeloid lymphoma

DrugsCiclosporin·Treosulfan·Mycophenolate Mofetil·Fludarabine

Institut Paoli Calmettes

Neoplasms

France

17/08/2026

Phase II

Efficacy of rituximab for remission maintenance in patients with primary angiitis of the central nervous system: an open-label, randomized, controlled trial comparing systematic rituximab infusions and azathioprine - MAINRIPAC

2026-525394-39-00Patients with primary angiitis of the central nervous system

DrugsAzathioprine·Rituximab

Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Nervous System Diseases

France

17/08/2026

Phase II

TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations

2026-525336-41-00Interstitial Lung Disease

DrugsAzithromycin·Hydroxychloroquine·Prednisolone·Prednisone

Assistance Publique Hopitaux De Paris

Respiratory Tract Diseases

France

14/08/2026

Phase II

Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)

2024-518027-30-00leptospirosis

DrugDoxycycline

CHU De Martinique

Bacterial Infections and Mycoses

France

13/08/2026

Phase II

SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics

2023-506001-19-00paraganglioma or pheochromocytoma with surgical indication

Assistance Publique Hopitaux De Paris

Hormonal diseases

France

10/08/2026

Phase II

A Phase 2 Multicentric Randomized Double-Blinded Efficacy and Safety Clinical Trial Comparing Several Doses of Aganirsen Eye Drops Emulsion to Extend Intravitreal Aflibercept Treatment Interval in Wet Age-Related Macular Degeneration (wAMD) Patients - SKY2 Study

2026-526775-27-00Wet Age-Related Macular Degeneration (wAMD) Patients

DrugAflibercept

Laboratoires Kol

Eye Diseases

France

10/08/2026

Phase II

VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study

2025-524318-27-00People with stage 1 or stage 2 T1D between the ages of 7 an…

DrugVerapamil

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

05/08/2026

Phase II

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

2025-525016-41-00Idiopathic Pulmonary Fibrosis

AstraZeneca AB

Respiratory Tract Diseases

Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark

04/08/2026

Phase II

A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.

2026-525161-40-00Drug resistant focal epilepsy related to focal cortical dys…

DrugPTI5803

PannTheraPi

Nervous System Diseases

France

31/07/2026

Phase II

A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer

2026-525382-47-00Small Cell Lung Cancer (SCLC)

Puma Biotechnology Inc.

Neoplasms

France, Poland, Spain

28/07/2026

Phase II

OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial

2025-524003-68-00Patients with newly or active diffuse Systemic sclerosis at…

DrugObinutuzumab

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

28/07/2026

Phase II

A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)

2025-522757-19-00LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA

Cancer Research UK

Neoplasms

Spain, France, Germany, Norway

27/07/2026

Phase II

Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK

2026-525862-23-00parkinson disease

DrugsDysport·NaCl

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

24/07/2026

Phase II

DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer

2025-525040-18-00triple‑negative breast cancer

DrugsEndoxan·Paclitaxel·Pembrolizumab

Institut Paoli Calmettes

Neoplasms

France

24/07/2026

Phase II

functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study

2025-523650-14-00Arthritis rheumatoid and finger osteoarthritis

Centre Jean Perrin

Not possible to specify

France

24/07/2026

Phase II

J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

2025-523258-15-00Breast Neoplasms

DrugsGoserelin·Tamoxifen

Eli Lilly & Co.

Neoplasms

Belgium, France, Italy, Germany, Ireland

21/07/2026

Phase II

DOXYCYCLINE PENETRATION INTO BONE AND JOINT.

2025-524744-36-00Patients requiring total hip arthroplasty for coxofemoral o…

DrugDoxycycline

Centre Hospitalier Universitaire De Caen Normandie

Bacterial Infections and Mycoses

France

20/07/2026

Phase II

A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

2025-523908-75-00Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

AstraZeneca AB

Cardiovascular Diseases

Germany, Italy, Spain, France, Sweden

20/07/2026

Phase II

A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.

2026-525162-21-00Drug resistant seizures associated to Focal Cortical Dyspla…

DrugPTI5803

PannTheraPi

Nervous System Diseases

France

20/07/2026

Phase II

SETRAPED : A prospective, multicenter study evaluating the efficacy and tolerance of transmucosal midazolam for proportionate palliative sedation in children with refractory symptoms

2025-523840-11-00Children with refractory symptoms

DrugMidazolam

Centre Leon Berard

Pathological Conditions, Signs and Symptoms

France

17/07/2026

Phase II

PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy

2025-523482-23-00neoplastic pleural effusion

Hospices Civils De Lyon

Neoplasms

France

16/07/2026

Phase II

Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)

2024-519985-35-00systemic lupus erythematosus pure membranous nephropathy

DrugObinutuzumab

Assistance Publique Hopitaux De Paris

Pathological Conditions, Signs and Symptoms

France

15/07/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke

2025-522734-31-00Acute Ischemic Stroke

Takeda Development Center Americas Inc.

Nervous System Diseases

Greece, Belgium, France, Germany

14/07/2026

Phase II

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease

2025-524139-38-00Antibody-mediated Kidney Disease

DrugSurovatamig

AstraZeneca AB

Immune System Diseases

France, Germany, Italy, Belgium, Poland, Spain

13/07/2026

Phase II

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

2025-523923-22-00Previously Treated, Unresectable, Locally Advanced or Metas…

Elevar Therapeutics Inc.

Neoplasms

France, Spain

09/07/2026

Phase II

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

2025-524285-18-00Advanced and/or Metastatic Solid Tumors with Homozygous MTA…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Belgium, Ireland, Germany, Norway, Italy, France, Spain

07/07/2026

Phase II

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

2025-523288-39-00Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Mediar Therapeutics Inc.

Immune System Diseases

Netherlands, Romania, Poland, France, Italy, Spain

06/07/2026

Phase II

Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial RSVaxID

2025-524374-42-00allogeneic haematopoietic stem cell transplant recipient, l…

DrugVaxzevria

Hospices Civils De Lyon

Surgical Procedures, Operative

France

06/07/2026

Phase II

Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 — ALACARTE trial)

2025-520783-17-01Adult patients diagnosed with uncomplicated acute appendici…

Assistance Publique Hopitaux De Paris

Therapeutics

France

06/07/2026

Phase II

Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment

2025-523921-17-00myeloproliferative neoplasms

DrugAnakinra

Centre Hospitalier Regional Et Universitaire De Brest

Hemic and Lymphatic Diseases

France

02/07/2026

Phase II

18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)

2025-523829-17-00Patients (male or female) ≥18 years old with Suspected func…

Centre Hospitalier Universitaire De Lille

Diagnosis

France

02/07/2026

Phase II

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

2025-522801-39-00Stage III Non Small Cell Lung Cancer

DrugDurvalumab

Intergroupe Francophone De Cancerologie Thoracique

Neoplasms

France

02/07/2026

Phase II

C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

2025-524686-24-00Small Cell Lung Cancer

DrugsPF-08634404·Etoposide·Carboplatin

Pfizer Inc.

Neoplasms

France, Italy, Spain

29/06/2026

Phase II

Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA

2025-524148-36-00Alcoholism

Institut National De La Sante Et De La Recherche Medicale

Mental Disorders

France

29/06/2026

Phase II

An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration

2025-525008-12-00Geographic atrophy secondary to age-related macular degener…

PulseSight Therapeutics

Eye Diseases

France

25/06/2026

Phase II

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).

2025-523403-29-00Non-cystic fibrosis bronchiectasis

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Poland, Spain, France, Netherlands, Germany

23/06/2026

Phase II

An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

2025-524164-37-00Relapsing-Remitting Multiple Sclerosis (RRMS)

DrugOcrelizumab

F. Hoffmann-La Roche AG

Nervous System Diseases

Poland, Germany, France

23/06/2026

Phase II

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).

2025-524488-18-00Muscle-invasive Bladder Cancer

Astellas Pharma Global Development Inc.

Neoplasms

Germany, France, Poland, Italy, Spain

22/06/2026

Phase II

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

2025-523479-49-00Colitis ulcerative

Merck Sharp & Dohme LLC

Digestive System Diseases

Italy, Greece, Netherlands, Poland, Germany, France

22/06/2026

Phase II

Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

2025-524713-88-00Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Verastem Inc.

Neoplasms

France

22/06/2026

Phase II

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

2025-522587-33-00Narcolepsy with Cataplexy (NT1)

Takeda Development Center Americas Inc.

Nervous System Diseases

Spain, Italy, France

22/06/2026

Phase II

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

2025-522951-24-00Osteogenesis Imperfecta

DrugAGA2115

Angitia Inc. Ltd.

Musculoskeletal Diseases

Netherlands, France, Denmark

22/06/2026

Phase II

A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)

2024-513496-40-00PARKINSON’S DISEASE

DrugPrasinezumab

Universitaetsklinikum Tuebingen AöR

Nervous System Diseases

Spain, Germany, Italy, Sweden, France, Luxembourg

18/06/2026

Phase II

Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial

2025-524889-25-00Osteoporotic Fracture

University Hospital Of Clermont-Ferrand

Musculoskeletal Diseases

France

17/06/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period

2025-522294-11-00Systemic sclerosis

Galderma S.A.

Skin and Connective Tissue Diseases

Poland, Italy, Bulgaria, France, Greece, Spain, Croatia

17/06/2026

Phase II

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

2025-524640-35-00Ulcerative colitis (Inflammatory Bowel Disease)

DrugsSPYPBO-101·SPY001·SPY002·SPY003

Spyre Therapeutics Inc.

Digestive System Diseases

Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania

16/06/2026

Phase II

Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis

2025-523616-36-00Transthyretin cardiac amyloidosis

Centre Hospitalier Universitaire De Nantes

Diagnosis

France

13/06/2026

Phase II

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

2025-524095-27-00HER2-negative, unresectable, recurrent, and/or metastatic g…

Gilead Sciences Inc.

Neoplasms

Spain, France

11/06/2026

Phase II

J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

2025-524404-29-00Ulcerative Colitis, Active Severe, Ulcerative Colitis, Acti…

Eli Lilly & Co.

Digestive System Diseases

Latvia, Portugal, Greece, France, Czechia, Italy, Poland, Slovakia, Hungary, Croatia, Lithuania

10/06/2026

Phase II

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period

2025-522301-37-00Nonsegmental vitiligo

Novartis Pharma AG

Skin and Connective Tissue Diseases

Germany, Spain, Netherlands, France, Italy

08/06/2026

Phase II

A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).

2025-523984-39-00Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Gilead Sciences Inc.

Neoplasms

Spain, Italy, France

08/06/2026

Phase II

C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

2024-518587-12-00MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (C…

Pfizer Inc.

Respiratory Tract Diseases

Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary

08/06/2026

Phase II

Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients with Septic Coagulopathy

2025-523397-16-00Septic Coagulopathy

Les Hopitaux Universitaires De Strasbourg

Investigative Techniques

France

05/06/2026

Phase II

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

2024-516570-30-00Relapsed/refractory T-cell Acute Lymphoblastic Leukemia

DrugsAsparaginase Erwinia chrysanthemi·Tofacitinib·Everolimus·Azacitidine

Centre Hospitalier De Versailles

Hemic and Lymphatic Diseases

Germany, France, Czechia, Netherlands, Spain

29/05/2026

Phase II

Intravenous iron in the management of drug-resistant restless legs syndrome: a randomized controlled delayed-start trial. IRON-RLS

2026-525613-31-00Restless legs syndrome

DrugFerric Carboxymaltose

Centre Hospitalier Universitaire De Montpellier

Nervous System Diseases

France

29/05/2026

Phase II

Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular glenohumeral corticosteroid injection in adhesive capsulitis.

2026-525317-31-00Retractile Capsulitis

Centre Hospitalier Universitaire De Nantes

Musculoskeletal Diseases

France

29/05/2026

Phase II

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis

2025-523400-72-00Cystic fibrosis

Vertex Pharmaceuticals Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark

29/05/2026

Phase II

Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)

2025-524378-40-00Locally advanced high‑risk stage III rectal adenocarcinoma …

DrugKortuc

Institut Gustave Roussy

Neoplasms

France

28/05/2026

Phase II

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)

2025-523539-20-00Low Grade Upper Tract Urothelial Carcinoma

Tyra Biosciences Inc.

Neoplasms

Bulgaria, France, Spain

28/05/2026

Phase II

Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.

2024-516796-33-00The medical condition studied in IMMUNO-BOS is Bronchioliti…

Hospital Foch

Respiratory Tract Diseases

France

27/05/2026

Phase II

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials

2025-523579-47-00moderate to severe rheumatoid arthritis (RA)

DrugAfimkibart

F. Hoffmann-La Roche AG

Immune System Phenomena

Italy, Spain, Germany, France, Denmark, Poland, Belgium

27/05/2026

Phase II

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

2025-521757-16-00Hallucinations and Delusions Associated with Alzheimer’s Di…

Maplight Therapeutics Inc.

Mental Disorders

Italy, Poland, Czechia, Portugal, Bulgaria, France, Slovakia, Romania, Hungary

27/05/2026

Phase II

POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug

2023-506420-93-00Chronic recurrent multifocal osteomyelitis (CRMO)

DrugZoledronic Acid

Assistance Publique Hopitaux De Paris

Musculoskeletal Diseases

France

26/05/2026

Phase II

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)

2025-524181-26-00relapsed/refractory multiple myeloma

C4 Therapeutics Inc.

Hemic and Lymphatic Diseases

Italy, France, Spain, Poland

25/05/2026

Phase II

UNLOCK - EPIBREAST, a phase II study of prifetrastat (PF-07248144), a KAT6 inhibitor, plus fulvestrant for advanced HR+/HER2- breast cancer with biomarkers analysis

2025-521982-29-00Adult patients with advanced hormone receptor positive (HR+…

DrugsPrifetrastat·Fulvestrant

Unicancer

Neoplasms

France

22/05/2026

Phase II

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

2025-525013-23-00Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

DrugPembrolizumab

Eikon Therapeutics Inc.

Neoplasms

Germany, Spain, Netherlands, Romania, Greece, Italy, Austria, Belgium, Bulgaria, France, Hungary, Poland

21/05/2026

Phase II

An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

2025-524367-20-00Adult patients with primary mitochondrial disease

Pharming Technologies B.V.

Metabolism

Belgium, Germany, Czechia, Spain, Denmark, Italy, France, Netherlands

21/05/2026

Phase II

An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up

2025-523280-38-00Thyroid Eye Disease

Amgen Inc.

Eye Diseases

Spain, Poland, France, Italy, Greece

20/05/2026

Phase II

PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

2025-523425-17-00Proteinuric kidney diseases

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Nutritional and Metabolic Diseases

Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia

19/05/2026

Phase II

Beamion 44: A randomized, open-label, multi-center Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus Pt-doublet with or without pembrolizumab (and potential other combinations) in treatment-naïve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations

2025-523567-38-00locally advanced or metastatic NSCLC

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Germany, France, Spain

19/05/2026

Phase II

An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

2024-519246-75-01Patients With Muscle-Invasive Bladder Cancer

AstraZeneca AB

Neoplasms

Italy, Spain, France, Netherlands

19/05/2026

Phase II

INCREDIBLE: INCREmental DIalysis and diet for a Better Life Experience; Clinical relevance of an “add-on” Ketosteril supplementation on incremental haemodialysis period in incident haemodialysis patients. An exploratory randomized controlled trial

2025-524093-41-00Incremental Haemodialysis

Centre Hospitalier Le Mans

Nutritional and Metabolic Diseases

France

18/05/2026

Phase II

Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum SHORT-LGV

2025-524978-42-00Asymptomatic anal LGV infection

DrugDoxycycline

Centre Hospitalier Universitaire De Bordeaux

Bacterial Infections and Mycoses

France

18/05/2026

Phase II

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

2024-518871-74-00Locally Advanced or Metastatic Solid Tumours that harbour M…

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Spain, France, Denmark

18/05/2026

Phase II

A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation

2025-522138-29-00Philadelphia positive Chronic Myeloid leukemia in Chronic P…

Novartis Pharma AG

Neoplasms

Spain, France, Germany, Poland, Italy, Netherlands, Greece, Hungary

18/05/2026

Phase II

Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy

2025-524317-88-00Multiple System Atrophy

Alterity Therapeutics Limited

Nervous System Diseases

France

13/05/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Prurigo Nodularis

2025-523404-74-00Prurigo Nodularis

Innocare Pharma Inc.

Skin and Connective Tissue Diseases

Belgium, Poland, Germany, France, Austria

13/05/2026

Phase II

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

2026-525213-31-00Esophageal squamous cell carcinoma

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Neoplasms

Czechia, Germany, France, Norway

12/05/2026

Phase II

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

2025-523895-22-00Non-small cell lung cancer (NSCLC), Cervical cancer (CC), M…

DrugsBNT324·Pumitamig

Dualitybio Inc.

Neoplasms

Italy, Poland, France, Spain, Germany

12/05/2026

Phase II

A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

2025-524843-11-00Non-Small Cell Lung Cancer

AstraZeneca AB

Neoplasms

France, Italy, Spain

06/05/2026

Phase II

A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration

2025-523704-77-00Geographic atrophy secondary to age-related macular degener…

Novartis Pharma AG

Eye Diseases

Bulgaria, Romania, Germany, Czechia, Spain, Poland, Italy, Hungary, France

04/05/2026

Phase II

"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment" "FAPGASTRO"

2025-524434-25-00gastric cancer

Drug[68Ga]Ga-FAPI-46

Centre Hospitalier Universitaire De Bordeaux

Neoplasms

France

30/04/2026

Phase II

Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity BRAVE

2025-524511-36-00Neurology

Hospices Civils De Lyon

Nervous System Diseases

France

30/04/2026

Phase II

Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease

2025-521154-42-00Sickle Cell Disease

CSL Behring LLC

Hemic and Lymphatic Diseases

Belgium, Netherlands, France, Italy

28/04/2026

Phase II

Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled Trial.(GAMMA-SLEEP)

2025-521967-11-00The study population includes adult ICU patients with a hos…

DrugNaCl

Assistance Publique Hopitaux De Paris

Mental Disorders

France

28/04/2026

Phase II

A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis

2024-514246-37-00Idiopathic pulmonary fibrosis (IPF)

Chiesi Farmaceutici S.p.A.

Respiratory Tract Diseases

Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania

27/04/2026

Phase II

Methylphenidate for Early Awakening in Coma (MEAWAKE)

2025-524937-19-00Coma due to acute brain injury

DrugMethylphenidate

Rigshospitalet

Nervous System Diseases

Austria, Denmark, Germany, France

27/04/2026

Phase II

Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors NA2C-TEP-IRM

2025-524602-15-00Neurology

Hospices Civils De Lyon

Nervous System Diseases

France

24/04/2026

Phase II

A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease

2025-520641-69-00Kidney disease

DrugsTacrolimus·Prednisolone·Obinutuzumab·Prednisone

Medizinische Universitaet Innsbruck

Immune System Diseases

Germany, Austria, France

23/04/2026

Phase II

NoELA_No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial

2025-523683-20-00Postmenopausal patients with small (pT1a-b pN0) hormone rec…

DrugsTamoxifen·Exemestane·Anastrozole·Letrozole

Unicancer

Neoplasms

France

21/04/2026

Phase II

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)

2025-523793-16-00Homeostatic iron regulator gene-related hereditary hemochro…

CSL Behring LLC

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands

20/04/2026

Phase II

IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease

2025-522790-10-00Non Small Cell Lung Cancer, Interstitial Lung Disease

Intergroupe Francophone De Cancerologie Thoracique

Neoplasms

France

17/04/2026

Phase II

A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease

2025-524302-15-00Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)

DrugVancomycin

MaaT PHARMA

Digestive System Diseases

Netherlands, Italy, France, Spain

17/04/2026

Phase II

METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0

2025-522655-26-00METAREM:Patients with advanced cancer, as defined as unrese…

Unicancer

Neoplasms

France

16/04/2026

Phase II

Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).

2025-522692-29-00Subacute Moderate to Severe Traumatic Brain Injury (TBI)

DrugCenegermin

Dompe' Farmaceutici S.p.A.

Nervous System Diseases

Italy, Denmark, Finland, France, Germany, Spain, Sweden, Poland

14/04/2026

Phase II

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer

2025-522107-18-00Locally advanced or metastatic Non-Small Cell Lung Cancer

DrugPegfilgrastim

Genmab A/S

Neoplasms

Germany, Hungary, Netherlands, France, Italy, Belgium, Spain, Poland

14/04/2026

Phase II

C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

2025-522965-31-00Atopic Dermatitis

Pfizer Inc.

Skin and Connective Tissue Diseases

Poland, Czechia, Germany, Bulgaria, France

14/04/2026

Phase II

A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)

2025-523117-28-00Relapsed or Refractory Multiple Myeloma

Glaxosmithkline Research & Development Limited

Neoplasms

France, Germany, Greece, Netherlands, Spain

13/04/2026

Phase II

A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)

2025-520976-25-00Relapsed/refractory multiple myeloma

DrugMezigdomide

Centre Hospitalier Universitaire De Saint Etienne

Hemic and Lymphatic Diseases

France

09/04/2026

Phase II

Retinoic acid and sperm production in infertile men

2024-519644-33-00oligozoospermia

Les Hopitaux Universitaires De Strasbourg

Not possible to specify

France

09/04/2026

Phase II

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.

2025-522867-13-00Non Small Cell Lung Cancer

Merus B.V.

Not possible to specify

Spain, Belgium, Netherlands, Poland, Italy, France

09/04/2026

Phase II

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)

2025-521090-14-00Patients with relapsed/refractory symptomatic multiple myel…

DrugsMezigdomide·Carfilzomib·Dexamethasone

Assistance Publique Hopitaux De Paris

Hemic and Lymphatic Diseases

France

08/04/2026

Phase II

ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.

2025-522288-13-00Patients with pretreated extensive-stage small cell lung ca…

ETOP IBCSG Partners Foundation

Neoplasms

France, Greece, Spain, Italy

08/04/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy

2025-522343-18-00Autosomal Dominant RYR1-Related Myopathy

Rycarma Therapeutics Inc.

Musculoskeletal Diseases

Netherlands, Spain, France, Germany

02/04/2026

Phase II

A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD328 in adult subjects with moderate to severe hidradenitis suppurativa

2025-521865-29-00moderate-to-severe hidradenitis suppurativa

Almirall S.A.

Skin and Connective Tissue Diseases

Bulgaria, Spain, France, Poland, Germany

01/04/2026

Phase II

PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults

2024-511510-20-00craniopharyngioma

DrugTovorafenib

Prinses Maxima Centrum voor Kinderoncologie B.V.

Neoplasms

Netherlands, France, Germany

25/03/2026

Phase II

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

2025-523803-31-00Advanced non-small cell lung cancer (NSCLC)

Shanghai Henlius Biotech Inc.

Therapeutics

Italy, Romania, Poland, Spain, France

25/03/2026

Phase II

MitOxyVit: Mitochondrial network modulation approach using hyperbaric oxygen (HBO) therapy and NNbUVB for treating vitiligo

2025-524709-34-00Vitiligo

Centre Hospitalier Universitaire De Nice

Skin and Connective Tissue Diseases

France

24/03/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

2025-520902-37-00Non-small cell lung cancer stage IV

Merck Sharp & Dohme LLC

Neoplasms

Italy, Spain, Poland, France

23/03/2026

Phase II

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulvestrant in Patients with Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8P Loss and Without a PIK3CA Mutation

2025-523013-28-00Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negativ…

F. Hoffmann-La Roche AG

Neoplasms

France, Italy, Poland, Germany, Spain

23/03/2026

Phase II

A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer

2025-524542-10-00Endometrial cancer

Acrivon Therapeutics Inc.

Neoplasms

Italy, Germany, Spain, France

23/03/2026

Phase II

PAROCAINE : Evaluation of the Clinical Tolerance of an Intra-Parotid Injection of Bupivacaine Combined with Dexamethasone After Parotidectomy for a Benign Tumor – Prospective Single-Center Cohort Study

2025-524358-32-00Indication opératoire validée de parotidectomie partielle p…

Centre Hospitalier Universitaire De Nimes

Otorhinolaryngologic Diseases

France

19/03/2026

Phase II

A Phase 2 Posology Study with Long-Term Extension in Participants with Well‑Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy from Standard Therapies

2025-523234-66-00Well-Controlled Recurrent Pericarditis

Kiniksa Pharmaceuticals GmbH

Therapeutics

Spain, Greece, Germany, France, Italy, Poland

19/03/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension

2024-514754-79-00Pulmonary Arterial Hypertension (PAH)

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Latvia, Belgium, France, Poland, Germany, Spain, Czechia

18/03/2026

Phase II

A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)

2025-522580-15-00Amyotrophic Lateral Sclerosis (ALS)

Zydus Therapeutics Inc.

Nervous System Diseases

Spain, Germany, Sweden, Ireland, Poland, Italy, Belgium, France, Netherlands

12/03/2026

Phase II

A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis

2024-518013-25-00Idiopathic Pulmonary Fibrosis

AbbVie Deutschland GmbH & Co. KG

Respiratory Tract Diseases

Greece, Italy, Sweden, Germany, Portugal, Spain, France, Hungary, Poland, Bulgaria, Romania

10/03/2026

Phase II

Upadacitinib in adult patients with erosive mucosal Lichen Planus and Lichen Planopilaris: a prospective multicenter randomized placebo-controlled study. (Upa30-LP)

2025-522870-35-00Lichen

Centre Hospitalier Universitaire De Nice

Skin and Connective Tissue Diseases

France

09/03/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa

2025-522831-33-00Hidradenitis Suppurativa

Takeda Development Center Americas Inc.

Skin and Connective Tissue Diseases

France, Poland, Netherlands, Germany

06/03/2026

Phase II

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

2025-521327-67-00Metastatic Castration-Resistant Prostate Cancer

F. Hoffmann-La Roche AG

Neoplasms

Germany, France, Italy, Spain

06/03/2026

Phase II

A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohn’s disease or ulcerative colitis

2025-522511-42-00Colitis Ulcerative, Crohn's disease

Sanofi-Aventis Recherche & Developpement

Digestive System Diseases

Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary

06/03/2026

Phase II

Pilot study of the efficacy of nicotinamide (vitamin B3) in Leber's hereditary optic neuropathy - NICOLHON

2025-524343-13-00Leber's Hereditary Optic Neuropathy

Centre Hospitalier Universitaire D'Angers

Eye Diseases

France

03/03/2026

Phase II

A phase II study of ficerafusp alfa (BCA 101) in combination with nivolumab in platinum refractory head and neck squamous cell carcinoma patients who progressed within 6 months after multimodal treatment for locally advanced disease ( BICARA)

2025-521437-88-00head and neck squamous cell carcinoma

Groupe Oncologie Radiotherapie Tete Cou

Neoplasms

France

02/03/2026

Phase II

Randomised EValuation of Therapies for microvAscuLar Injury in STEACS – REVITALISE Study

2025-522060-32-00STEMI (ST elevated Myocardial Infarction)

DrugAdenosine

CorFlow Therapeutics AG, CorFlow Therapeutics AG

Cardiovascular Diseases

Netherlands, Spain, France

02/03/2026

Phase II

An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301. AIRPHRODITE

2025-522896-27-00Asthma

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Poland, Italy, Belgium, Sweden, Hungary, France, Germany, Spain, Denmark

02/03/2026

Phase II

A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa

2025-522695-83-00Hidradenitis suppurativa

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Hungary, Spain, France, Belgium, Sweden, Germany, Italy

02/03/2026

Phase II

C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis

2025-523100-77-00Ulcerative Colitis

Pfizer Inc.

Digestive System Diseases

Finland, Poland, France, Germany, Italy, Slovakia

27/02/2026

Phase II

A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis

2025-524784-20-00Recurrent Pericarditis

Zomagen Biosciences Limited

Cardiovascular Diseases

Belgium, France, Greece, Spain, Italy

27/02/2026

Phase II

STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients

2024-516215-24-00TAkayasu ARteritiS

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

26/02/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)

2025-522835-32-00Suspected Invasive Mould Infection

Elion Therapeutics Inc.

Bacterial Infections and Mycoses

Belgium, France, Spain, Italy

26/02/2026

Phase II

Effect of H2 inhalation therapy on early recurrence after atrial fibrillation ablation. Multicenter, open-label, randomized phase II controlled trial.

2024-520131-33-00atrial fibrillation

Centre Hospitalier Universitaire Grenoble Alpes

Cardiovascular Diseases

France

25/02/2026

Phase II

J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease

2025-522204-24-00Neoplasms, Drug-Related Side Effects and Adverse Reactions,…

Eli Lilly & Co.

Neoplasms

Romania, Spain, France, Italy

23/02/2026

Phase II

A phase 2a exploratory study of TAR-0520 gel in prevention of Hand and Foot Syndrome

2025-524008-32-00Capecitabine-induced hand and foot syndrome

Tarian Pharma

Skin and Connective Tissue Diseases

France

16/02/2026

Phase II

A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above

2025-521416-19-00Recurrence of Clostridioides difficile Infection

AstraZeneca AB

Bacterial Infections and Mycoses

Greece, Spain, France, Germany, Italy, Hungary, Denmark, Sweden

16/02/2026

Phase II

A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment.

2025-523231-19-00Cutaneous Squamous Cell Carcinoma

Philogen S.p.A.

Neoplasms

Italy, Germany, Greece, Spain, Austria, France, Netherlands

10/02/2026

Phase II

A Phase 2 controlled randomized study of the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF intralesional injections for the treatment of locally advanced basal cell carcinoma patients.

2025-523229-16-00locally advanced basal cell carcinoma patients

Philogen S.p.A.

Neoplasms

Greece, Italy, Germany, Spain, Netherlands, Austria, France

10/02/2026

Phase II

A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Basal Cell Carcinoma patients progressed on or intolerant to systemic treatment.

2025-523230-77-00Patients with locally advanced Basal Cell Carcinoma (LaBCC)…

Philogen S.p.A.

Neoplasms

Germany, Italy, Greece, Spain, Austria, France

10/02/2026

Phase II

A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to less than 18 Years of age With Generalized Myasthenia Gravis (gMG)

2025-520993-20-00Generalized Myasthenia Gravis

DrugInebilizumab

Amgen Inc.

Nervous System Diseases

Spain, Italy, Poland, France

09/02/2026

Phase II

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI)- (299AR201-TRANSPIRE)

2025-521742-15-00Treatment of Late Isolated Microvascular Inflammation in Re…

Biogen Idec Research Limited

Immune System Diseases

Germany, Austria, Spain, Czechia, France

09/02/2026

Phase II

A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis

2025-522892-27-00Bronchiectasis

GSK PLC

Respiratory Tract Diseases

Denmark, France, Spain, Italy, Germany, Poland

09/02/2026

Phase II

A PET-MRI study of serotoninergic brainstem pathway in patients with Dravet Syndrome - DRAPETONINE

2025-524199-40-00neurology

Hospices Civils De Lyon

Nervous System Diseases

France

06/02/2026

Phase II

An Open-Label Extension, Multi-centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants with Multiple System Atrophy

2025-521642-14-00Multiple System Atrophy

Teva Branded Pharmaceutical Products R&D LLC

Nervous System Diseases

France, Germany, Italy, Spain

04/02/2026

Phase II

An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer with Liver Dominant Disease

2025-521966-91-00Refractory Metastatic Breast Cancer with Liver Dominant Dis…

Delcath Systems Inc.

Neoplasms

Italy, Spain, Sweden, France, Germany

04/02/2026

Phase II

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)

2025-521560-36-00Type 1 Diabetes

Sab Biotherapeutics Inc.

Nutritional and Metabolic Diseases

Austria, Germany, Poland, Italy, Denmark, Spain, Belgium, Finland, France, Lithuania, Slovenia

02/02/2026

Phase II

Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), with biomarker analysis to characterize response/resistance (UNLOCK ASP3082)

2025-522533-54-00Metastatic Non-small cell lung cancer (NSCLC) and Pancreati…

Institut Gustave Roussy

Neoplasms

France

28/01/2026

Phase II

A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis

2025-521636-10-00Progressive Forms of Multiple Sclerosis (PMS)

F. Hoffmann-La Roche AG

Nervous System Diseases

Germany, Spain, France, Hungary, Italy, Poland, Portugal

28/01/2026

Phase II

SARUPANC - A multicentric, single arm, phase II trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer

2024-516558-24-00Pancreatic (PAAD)

Centre Leon Berard

Neoplasms

France

23/01/2026

Phase II

Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome

2025-522556-10-01Ocular Sequelae in Lyell syndrome

DrugTildrakizumab

TOXILYON

Eye Diseases

France

23/01/2026

Phase II

Master Protocol: A Phase 1b / 2, Multicenter, Multi Arm Study of Evorpacept in Combination with Anti-cancer Therapies in Advanced / Metastatic Malignancies (ASPEN-09) Substudy Protocol: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer (ASPEN-09-03)

2025-522012-16-00Breast Cancer

Alx Oncology Holdings Inc.

Neoplasms

Spain, Italy, France

23/01/2026

Phase II

A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of oral VH4524184 Coadministered with Emtricitabine and Tenofovir Alafenamide in Treatment Naïve Viremic Persons with HIV-1.( INNOVATE Study)

2025-521918-26-00HIV Infections

Viiv Healthcare UK Limited

Virus Diseases

Spain, Belgium, France, Germany, Italy, Portugal, Poland

23/01/2026

Phase II

Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a pilot study

2025-522743-18-00Gambling disorder

Centre Hospitalier Universitaire De Nantes

Behavior and Behavior Mechanisms

France

21/01/2026

Phase II

J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma

2025-522640-41-00Asthma

Eli Lilly & Co.

Respiratory Tract Diseases

Germany, Netherlands, France, Poland

21/01/2026

Phase II

A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)

2025-521606-18-00Ovarian Cancer

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Spain, Czechia, France, Belgium, Denmark

19/01/2026

Phase II

A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis

2025-521503-43-00Atopic dermatitis

Novartis Pharma AG

Skin and Connective Tissue Diseases

France, Germany, Poland, Czechia, Bulgaria

14/01/2026

Phase II

A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA)

2025-522232-13-00Sepsis-associated acute kidney injury (AKI)

DrugAZD4144

AstraZeneca AB

Not possible to specify

Germany, France, Spain, Italy, Belgium, Czechia, Greece, Denmark, Hungary

14/01/2026

Phase II

Efficacy and safety of Remimazolam compared to Ketamine and Propofol in Rapid Sequence Induction. A monocentric pilot randomised-controlled study

2025-521602-18-00Rapid Sequence Induction in operating room

DrugsRemimazolam·Ketamine·Propofol

Centre Hospitalier Universitaire De Nantes

Anesthesia and Analgesia

France

06/01/2026

Phase II

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)

2025-520675-86-00Unresectable or Metastatic Hepatocellular Carcinoma and Com…

CatalYm GmbH

Neoplasms

Germany, France, Italy, Spain

23/12/2025

Phase II

A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

2025-522333-61-00Hidradenitis suppurativa

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Poland, Hungary, Netherlands, Germany, Czechia, Spain, France, Italy, Greece

22/12/2025

Phase II

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.

2025-522309-40-00Non-segmental vitiligo

Takeda Development Center Americas Inc.

Skin and Connective Tissue Diseases

Poland, Italy, Spain, France

19/12/2025

Phase II

Is [18F]-DPA-714 PET a good marker of neuroinflammation in autoimmune encephalitis? (EAI-714)

2025-522768-33-00autoimmune encephalitis

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

15/12/2025

Phase II

A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects with Deletion- or Nondeletion-type Angelman Syndrome

2024-519393-39-00Angelman Syndrome

Ultragenyx Pharmaceutical Inc.

Nervous System Diseases

Portugal, Italy, France

11/12/2025

Phase II

An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors (EZHiSWITCH)

2024-519788-16-00Adult patients with histologically/cytologically confirmed …

Institut Gustave Roussy

Neoplasms

France

09/12/2025

Phase II

SYMBOL CLINICAL : Treatment of severe ocular chemical burns by subconjunctival injection of allogeneic mesenchymal stem cells: a multicentre, single-arm, open-label phase II trial

2023-509713-37-00Patient with severe eye chemical burns

DrugsRemifentanil·Paracetamol·Midazolam·Propofol

Hopital Fondation Adolphe De Rothschild

Eye Diseases

France

09/12/2025

Phase II

An Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PTX-100 Monotherapy in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma.

2025-521852-45-00Cutaneous T-Cell Lymphoma

Prescient Therapeutics Limited

Neoplasms

Italy, France

08/12/2025

Phase II

Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)

2024-518231-11-00Immune thrombocytopenia (ITP) Warm autoimmune hemolytic an…

Novartis Pharma AG

Hemic and Lymphatic Diseases

Germany, Czechia, Belgium, Spain, Italy, Bulgaria, Romania, France, Hungary

08/12/2025

Phase II

(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome

2024-516471-33-00Chronic kidney disease, Alport Syndrome

Bayer AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Italy, Poland, Czechia, Germany, Portugal, France

05/12/2025

Phase II

A Phase II, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients with Multiple Sclerosis

2024-517980-22-00Multiple Sclerosis (MS)

F. Hoffmann-La Roche AG

Immune System Diseases

Poland, Italy, France, Spain, Germany

05/12/2025

Phase II

A PHASE 2A, OPEN-LABEL SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)

2025-522074-37-00Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertensi…

Allrock Bio Inc.

Cardiovascular Diseases

Spain, Italy, Poland, France, Latvia, Germany

04/12/2025

Phase II

A dose-ranging randomized, open-label study evaluating the effect of bilateral intravitreal injection of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy – The REVISE Study

2025-523339-20-00Leber Hereditary Optic Neuropathy due to mutations in the m…

Gensight Biologics

Eye Diseases

France

02/12/2025

Phase II

C5001004 - A Phase 2, Open-Label Extension Study to Investigate the Safety and Efficacy of PF-07868489 Administered to Adult Participants With Pulmonary Arterial Hypertension

2025-521155-23-00Pulmonary Arterial Hypertension

Pfizer Inc.

Cardiovascular Diseases

Italy, Czechia, Germany, Greece, Spain, Belgium, France

02/12/2025

Phase II

A phase 2, multicenter, randomized, placebo-controlled, double-blind study to investigate the safety, pharmacodynamics, and preliminary efficacy of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease.

2025-522146-40-00Late-onset Pompe disease.

Shionogi B.V.

Nutritional and Metabolic Diseases

Belgium, Germany, Denmark, France, Italy, Spain, Netherlands

01/12/2025

Phase II

A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants

2024-517393-13-00Autosomal Dominant Polycystic Kidney Disease (ADPKD)

DrugVX-407

Vertex Pharmaceuticals Inc.

Genetic Phenomena

France, Germany, Italy, Belgium, Spain, Netherlands

28/11/2025

Phase II

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

2025-520730-28-00Common EGFR-Mutated Locally Advanced or Metastatic Non-Smal…

Janssen Cilag International

Neoplasms

Germany, Spain, Finland, Greece, Portugal, Italy, Belgium, Poland, France

27/11/2025

Phase II

A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma

2025-522054-40-00Previously treated advanced melanoma

Iovance Biotherapeutics Inc.

Skin and Connective Tissue Diseases

France, Italy, Germany, Spain

26/11/2025

Phase II

BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch

2024-514848-88-00Folliculitis decalvans

DrugsUstekinumab·Baricitinib·Adalimumab

Assistance Publique Hopitaux De Paris

Therapeutics

France

24/11/2025

Phase II

PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial

2025-521371-31-00Sepsis

Assistance Publique Hopitaux De Paris

Virus Diseases

France

24/11/2025

Phase II

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors

2025-521034-28-00Moderate to Severe Rheumatoid Arthritis (RA)

DrugAfimkibart

F. Hoffmann-La Roche AG

Immune System Phenomena

Italy, Denmark, France, Poland, Germany, Spain, Belgium

23/11/2025

Phase II

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants with PMN (Primary Membranous Nephropathy) who are at a High Risk for Disease Progression (AUTUMN)

2025-520780-40-00Primary Mebranous Nephropathy (PMN)

Alexion Pharmaceuticals Inc.

Immune System Diseases

Spain, France, Italy

20/11/2025

Phase II

A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM

2024-515125-28-00Non-obstructive hypertrophic cardiomyopathy

Imbria Pharmaceuticals Inc.

Cardiovascular Diseases

Austria, Germany, Belgium, France, Portugal, Spain, Netherlands, Italy, Poland

20/11/2025

Phase II

Phase 2, Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Tarperprumig in Adult Participants with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

2025-521706-17-00Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasc…

Alexion Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Spain, France, Italy, Germany, Poland

17/11/2025

Phase II

FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.

2025-521322-14-00Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1…

DrugsIvosidenib·Azacitidine

French Innovative Leukemia Organization

Hemic and Lymphatic Diseases

France

17/11/2025

Phase II

ALaDIN - Use of low doses of interleukin-2 in autism spectrum disorders

2025-522841-23-00Autism Spectrum disorder ASD

Assistance Publique Hopitaux De Paris

Mental Disorders

France

17/11/2025

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE 2B TRIAL TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AEF0217 FOR 24 WEEKS IN ADULTS AND OLDER ADOLESCENTS WITH DOWN SYNDROME

2025-521013-10-00Treatment of behavioural and cognitive impairments in Down …

Aelis Farma

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Italy, France

17/11/2025

Phase II

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)

2024-517711-70-01Narcolepsy without Cataplexy (NT2)

Takeda Development Center Americas Inc.

Nervous System Diseases

Spain, Italy, France

14/11/2025

Phase II

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who Participated in Previous Afimkibart Clinical Trials

2025-520771-59-00Atopic Dermatitis

F. Hoffmann-La Roche AG

Skin and Connective Tissue Diseases

Italy, Poland, Germany, Spain, France

13/11/2025

Phase II

A Phase 2, open-label, multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206)

2024-516551-41-00Patients with HER2-expressing solid tumors

Jazz Pharmaceuticals Ireland Limited

Neoplasms

Spain, France, Italy

13/11/2025

Phase II

A DOSE-DETERMINATION STUDY OF SUGAMMADEX AS A ROCURONIUM DECURARIZATION AGENT IN CHILDREN UNDER 2 YEARS OF AGE

2025-521946-82-00Non-urgent non-cardiac surgical procedure or relative emerg…

Centre Hospitalier Universitaire De Caen Normandie

Anesthesia and Analgesia

France

12/11/2025

Phase II

BRECHE : Efficacy of sphenopalatine block compared to blood patch in the management of post-dural puncture syndrome.

2025-522168-34-00Post-dural puncture syndrome

University Hospital Of Clermont-Ferrand

Therapeutics

France

12/11/2025

Phase II

MATVAC-1 : EVALUATION OF UCPVAX VACCINE +/- PEMBROLIZUMAB COMBINED WITH STANDARD TREATMENT AS ADJUVANT THERAPY IN PATIENTS WITH UNMETHYLATED MGMT GLIOBLASTOMA

2024-514399-42-00Glioblastoma

DrugsUCPVax·Temozolomide·Pembrolizumab

Centre Hospitalier Regional Universitaire

Immune System Diseases

France

12/11/2025

Phase II

A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)

2025-521737-91-00Neoplasm malignant with KRAS G12C mutation

Merck Sharp & Dohme LLC

Neoplasms

Norway, Spain, Sweden, Italy, Denmark, France, Poland, Germany, Greece

12/11/2025

Phase II

Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

2025-521242-26-00Moderately to Severely Active Ulcerative Colitis

DrugsSPYPBO-101·SPY001·SPY002·SPY003

Spyre Therapeutics Inc.

Digestive System Diseases

Belgium, Hungary, Lithuania, Netherlands, Croatia, Czechia, Bulgaria, Romania, Spain, France, Austria, Italy, Greece, Poland, Germany, Slovakia

10/11/2025

Phase II

A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 in Adult Participants with Moderate or Severe Asthma (the POLARIS trial)

2025-521391-58-00Asthma

Windward Bio AG

Respiratory Tract Diseases

Germany, France, Sweden, Bulgaria, Spain

10/11/2025

Phase II

A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR

2024-519511-33-00Patients will be included with a stable but active disease …

Centre Hospitalier Universitaire De Montpellier

Immune System Diseases

France

07/11/2025

Phase II

IFCT-2402 LAG-MAPS A non-comparative phase IIR trial assessing fianlimab plus cemiplimab plus pemetrexed-platinum chemotherapy or cemiplimab plus pemetrexed-platinum chemotherapy for treatment-naive Pleural Mesothelioma (PM) patients

2024-519208-29-00Pleural mesothelioma

Intergroupe Francophone De Cancerologie Thoracique

Neoplasms

France

06/11/2025

Phase II

Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL). A phase II FILO trial

2025-521199-80-00Patients with previously untreated symptomatic chronic lymp…

DrugPirtobrutinib

French Innovative Leukemia Organization

Hemic and Lymphatic Diseases

France

05/11/2025

Phase II

An Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HR-positive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)

2025-521904-23-00Locally Advanced Inoperable or Metastatic Breast Cancer Ref…

AstraZeneca AB

Neoplasms

Spain, France, Italy

05/11/2025

Phase II

Efficacy and safety assessment of T1695 ophthalmic suspension, versus Ciclosporin ophthalmic emulsion, in participants with moderate to severe Vernal Keratoconjunctivitis (VKC)

2025-521567-12-00Vernal Keratoconjunctivitis (VKC)

DrugCiclosporin

Laboratoires Thea

Eye Diseases

Spain, Italy, Bulgaria, France, Greece

04/11/2025

Phase II

A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa

2025-521293-34-00Moderate-to-severe hidradenitis suppurativa

Almirall S.A.

Skin and Connective Tissue Diseases

Germany, Italy, Ireland, Poland, Spain, France

03/11/2025

Phase II

A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization

2025-523009-14-00Bronchiectasis with chronic pseudomonas aeruginosa coloniza…

AstraZeneca AB

Respiratory Tract Diseases

Netherlands, Italy, Greece, Denmark, Belgium, Spain, France, Germany

31/10/2025

Phase II

A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults with Lewy Body Dementia Psychosis (LBDP)

2025-521710-25-00Lewy Body Dementia Psychosis (LBDP)

Acadia Pharmaceuticals Inc.

Nervous System Diseases

Bulgaria, Czechia, Italy, France

29/10/2025

Phase II

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

2025-521144-38-00Primary Central Nervous System Lymphoma

Bristol-Myers Squibb Services Unlimited Company

Nervous System Diseases

France, Germany

29/10/2025

Phase II

NEOREM/NEO-1 - NEOREM : Neo-adjuvant Adaptive Master Trial for Localized Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / NEO-1 : Neo-adjuvant intratumoral Anti-CTLA4 + Anti-PD1 treatment in patients with localized melanoma

2025-522127-95-00NEOREM: Localized solid malignancies that are eligible to r…

Unicancer

Neoplasms

France

28/10/2025

Phase II

An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with Still’s disease

2024-520208-25-00Still’s disease

Novartis Pharma AG

Immune System Diseases

Italy, Netherlands, Spain, France, Germany

28/10/2025

Phase II

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

2024-519820-26-00Hallucinations and Delusions Associated with Alzheimer’s Di…

Maplight Therapeutics Inc.

Nervous System Diseases

France, Czechia, Slovakia, Hungary, Portugal, Romania, Bulgaria, Italy, Poland

27/10/2025

Phase II

BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

2024-520308-24-00Adult patients with persistent dyspnea more than 3 months a…

DrugBevacizumab

Assistance Publique Hopitaux De Paris

Virus Diseases

France

24/10/2025

Phase II

LUSPARA - A basket phase II clinical trial evaluating Luspatercept in patients affected with rare inherited anemias

2024-520200-26-00Inherited anemias

Eurobloodnet Association

Hemic and Lymphatic Diseases

Italy, France

24/10/2025

Phase II

ALTER : A Phase 2, Multicenter, Randomized, Open-label trial assessing sacituzumab-govitecan and trastuzumab-deruxtecan combinaison in an ALTERnating regimen for patients with metastatic or locally advanced Her2-low triple-negative breast Cancer

2025-521909-40-00Patients with metastatic or locally advanced HER2-low tripl…

Unicancer

Neoplasms

France

23/10/2025

Phase II

Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor

2025-520468-16-00Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced U…

Genmab A/S

Neoplasms

France, Spain, Netherlands, Germany

23/10/2025

Phase II

A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.

2025-521107-42-00Alzheimer's Disease

Glaxosmithkline Research & Development Limited

Nervous System Diseases

Sweden, Norway, Italy, France, Spain, Finland, Netherlands, Germany

23/10/2025

Phase II

Preoperative use of Romiplostim in thrombocytopenic patients undergoing cardiac surgery. A Phase 3, multicenter randomized double-blinded controlled against placebo study

2024-517710-15-00thrombocytopenic patients undergoing cardiac surgery

Centre Hospitalier Universitaire De Nantes

Surgical Procedures, Operative

France

22/10/2025

Phase II

A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants with Advanced Prostate Cancer

2024-517653-27-00Prostate Cancer

Astellas Pharma Global Development Inc.

Neoplasms

Italy, Poland, Spain, France, Germany

22/10/2025

Phase II

A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA) (OPAL)

2024-520130-29-00Spinal Muscular Atrophy

Scholar Rock Inc.

Musculoskeletal and Neural Physiological Phenomena

Belgium, France, Italy, Spain, Netherlands

21/10/2025

Phase II

BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study

2024-520128-27-00colorectal adenocarcinoma

Association Gercor

Digestive System Diseases

France

20/10/2025

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months

2024-512261-14-00Hypochondroplasia

Biomarin Pharmaceutical Inc.

Genetic Phenomena

Germany, Italy, France

20/10/2025

Phase II

EPIK-P4: A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

2024-519960-42-00PIK3CA-Related Overgrowth Spectrum (PROS)

Novartis Pharma AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Italy, Netherlands, Belgium, Spain, Austria, Germany, France

20/10/2025

Phase II

PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.

2024-519753-11-00Resectable borderline pancreatic adenocarcinoma

Fondation Franc.Cancerologie Digestive

Digestive System Diseases

France

17/10/2025

Phase II

Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring

2024-519133-29-00Focal epilepsy

Fondation A De Rothschild

Nervous System Diseases

France

17/10/2025

Phase II

Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial, ADEM2 study

2022-502362-24-00Erosive osteoarthritis

Centre Hospitalier Universitaire De Nice

Musculoskeletal Diseases

France

17/10/2025

Phase II

A phase 2, two-part study to assess the safety, antiviral biomarker responses, and efficacy of inhaled SNG001 for the treatment of patients with a confirmed respiratory virus infection undergoing invasive mechanical ventilation

2024-520375-27-00Lower respiratory tract viral infections

Synairgen Research Limited

Virus Diseases

Netherlands, France, Spain, Belgium

15/10/2025

Phase II

Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage. The INFINITE Study

2025-521923-58-00Intracerebral hemorrhage.

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

10/10/2025

Phase II

PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.

2024-519258-35-00stomach cancer, Esophage, gastro-oesophageal junction adeno…

Fondation Franc.Cancerologie Digestive

Digestive System Diseases

France

08/10/2025

Phase II

PRODIGE 115 (FFCD 2406) ULYSSE : A phase II, open-label, non-comparative, randomized study of second-line doublet chemotherapy (FOLFOX or FOLFIRI) plus Fruquintinib versus doublet chemotherapy (FOLFOX or FOLFIRI) plus Bevacizumab in metastatic colorectal cancer

2025-522108-26-00métastatique colorectal cancer

Fondation Franc.Cancerologie Digestive

Digestive System Diseases

France

08/10/2025

Phase II

GFM-VEXAS-MMB: A single-arm phase II with safety run-in multicenter study of momelotinib in patients with VEXAS syndrome with or without associated myelodysplastic syndrome

2024-519779-24-00VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOM…

Groupe Francophone Des Myelodysplasies

Immune System Diseases

France

08/10/2025

Phase II

C4921003 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched-Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948 in Adults with Heart Failure (BRANCH-HF)

2024-518438-94-00Heart failure

Pfizer Inc.

Cardiovascular Diseases

France, Spain, Bulgaria, Poland, Hungary, Czechia

08/10/2025

Phase II

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

2025-521277-14-00Non-muscle invasive bladder cancer (NMIBC)

Tyra Biosciences Inc.

Neoplasms

Italy, Spain, France

08/10/2025

Phase II

CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders

2025-521161-27-00Children and adolescents with severe neurodevelopmental dis…

DrugCannabidiol

Assistance Publique Hopitaux De Paris

Behavior and Behavior Mechanisms

France

07/10/2025

Phase II

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

2024-519278-37-00Lupus Nephritis, Systemic Lupus Erythematosus

Celgene Corp.

Immune System Diseases

France, Spain, Portugal, Germany, Belgium, Poland, Italy, Denmark, Austria

06/10/2025

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-europe/country/france

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,788 trial records at the last sync on 08 Nov 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 274 of those trials with a site in France that also match the filters currently applied.

How many recently authorised EU trials have a site in France?

274 of the 2,557 most recently authorised trials in this register list a site in France and match the filters applied; 0 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (France), 274 trials
Phase	Trials	Share
Phase II	274	100%

Most active sponsors

Lead sponsors with the most trials (France)
Lead sponsor	Trials
Assistance Publique Hopitaux De Paris	17
Novartis Pharma AG	11
F. Hoffmann-La Roche AG	10
AstraZeneca AB	9
Pfizer Inc.	7
Centre Hospitalier Universitaire De Nantes	6
Hospices Civils De Lyon	6
Takeda Development Center Americas Inc.	6
Unicancer	6
Eli Lilly & Co.	5

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.